Page last updated: 2024-09-03

glycylglutamine and u-50488

glycylglutamine has been researched along with u-50488 in 1 studies

Compound Research Comparison

Studies
(glycylglutamine)
Trials
(glycylglutamine)
Recent Studies (post-2010)
(glycylglutamine)
Studies
(u-50488)
Trials
(u-50488)
Recent Studies (post-2010) (u-50488)
1048141,6643209

Protein Interaction Comparison

ProteinTaxonomyglycylglutamine (IC50)u-50488 (IC50)
Delta-type opioid receptorRattus norvegicus (Norway rat)2.15
Kappa-type opioid receptorMus musculus (house mouse)0.0027
Mu-type opioid receptorRattus norvegicus (Norway rat)2.15
Kappa-type opioid receptorRattus norvegicus (Norway rat)0.7171
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.0958
Kappa-type opioid receptorHomo sapiens (human)0.0537

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cavun, S; Göktalay, G; Hamilton, JR; Levendusky, MC; Millington, WR1

Other Studies

1 other study(ies) available for glycylglutamine and u-50488

ArticleYear
Glycyl-glutamine inhibits nicotine conditioned place preference and withdrawal.
    European journal of pharmacology, 2006, Jan-13, Volume: 530, Issue:1-2

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Avoidance Learning; Conditioning, Psychological; Dipeptides; Dose-Response Relationship, Drug; Injections, Intraventricular; Injections, Subcutaneous; Male; Mecamylamine; Nicotine; Nicotinic Agonists; Nicotinic Antagonists; Peptides, Cyclic; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Substance Withdrawal Syndrome; Time Factors

2006